News
ConvaTec Enhances Innovation Management with Anaqua
Anaqua, the leading innovation and intellectual property management technology provider, announced that global medical products and technologies group ConvaTec will use Anaqua’s AQX platform to help more effectively manage their valuable patent and trademark portfolios.
The agreement further strengthens Anaqua’s...
Clinical Trials
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Pfizer Inc. and BioNTech SE announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21...
Drug Research
FDA Approves Samsung Bioepis and Biogens BYOOVIZ, LUCENTIS Biosimilar
Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i , for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO),...
Clinical Trials
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
Valneva SE, a specialty vaccine company, announced that it has completed recruitment of the initial cohort of elderly participants in Valneva’s Phase 3 trial, VLA2001-304, of its inactivated COVID-19 vaccine candidate, VLA2001.
300 volunteers aged 56 years and older have...
News
Glenmark completes PMS study of Covid-19 drug Favipiravir
Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir (FabiFlu®) in India. The PMS study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir...
News
EUA for Lilly’s bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
The U.S. FDAhas expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis (PEP) in certain individuals for the prevention of SARS-CoV-2 infection, Eli Lilly and Company (NYSE: LLY)...
News
LANXESS India wins big at the Indian Chemical Council awards
Specialty chemicals company LANXESS India has been conferred with three prestigious awards from the Indian Chemical Council (ICC), recognizing the organization’s commitment and outstanding performance specifically in the areas of Health & Safety. LANXESS India won awards for Excellence...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read